Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 21%
Hold 50%
Sell 7%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb is projected to see steady growth through 2028, exceeding consensus estimates in both total revenue and EPS. With a strong pipeline in immuno-oncology and promising results from recent drug trials, BMY has increased conviction in its transformative potential and has overcome previous overhangs. In-depth interviews with experts also suggest significant market potential for its CELMoD drugs, and recent validation of the Factor XIa class in SSP further supports the company's potential for success. Overall, with strong management guidance and a solid dividend, BMY is a buy for investors looking for potential high-reward Ph 3 catalysts.

Bears say

Bristol-Myers Squibb is facing potential downside risks due to the possibility of competitors obtaining better results in their rare cardiovascular, inflammation, and oncology treatments, as well as the potential failure of mid- or late-stage pipeline programs. Furthermore, regulatory delays and macro/policy-related risks could also impact the company's performance. Given the company's high dependence on the US market and its focus on immuno-oncology, any negative outcomes in these areas could significantly impact Bristol-Myers Squibb's financials and overall outlook.

Bristol-Myers (BMY) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 14 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Jul 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.